Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 14, 2024

Safety and Efficacy of Lasofoxifene vs Fulvestrant for Treating Women With ESR1-Mutated, ER+/HER2− MBC

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
Ann. Oncol 2023 Dec 01;34(12)1141-1151, MP Goetz, NA Bagegni, G Batist, A Brufsky, MA Cristofanilli, S Damodaran, BR Daniel, GF Fleming, WJ Gradishar, SL Graff, MT Grosse Perdekamp, E Hamilton, S Lavasani, A Moreno-Aspitia, T O'Connor, TJ Pluard, HS Rugo, SL Sammons, LS Schwartzberg, DG Stover, GA Vidal, G Wang, E Warner, R Yerushalmi, PV Plourde, DJ Portman, EN Gal-Yam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading